Liminatus Pharma, Inc. (LIMN)
0.3765
-0.11
(-22.39%)
USD |
NASDAQ |
Feb 13, 16:00
0.3845
+0.01
(+2.12%)
After-Hours: 20:00
Liminatus Pharma Cash from Financing (Quarterly) : 0.00 for Sept. 30, 2025
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| CDT Equity, Inc. | 5.997M |
| LENZ Therapeutics, Inc. | 0.598M |
| Oruka Therapeutics, Inc. | 169.91M |
| Maze Therapeutics, Inc. | 143.76M |
| MapLight Therapeutics, Inc. | 198.06M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.6006M |
| Cash from Investing (Quarterly) | -0.0131M |
| Free Cash Flow | -10.38M |
| Free Cash Flow Per Share (Quarterly) | -0.0227 |
| Free Cash Flow to Equity (Quarterly) | -0.6137M |
| Free Cash Flow to Firm (Quarterly) | -0.5946M |
| Free Cash Flow Yield | -132.2% |